Recommendations for Ensuring Equitable Access to Oral Therapies for Treating COVID-19

Many hospitals and health departments are experiencing the greatest strain on their systems and workforce since the COVID-19 pandemic was declared nearly two years ago.

Infectious Diseases Society of America Announces Next Editor-in-Chief of The Journal of Infectious Diseases

IDSA is pleased to announce that Cynthia L. Sears, MD, FIDSA, has been selected as the next editor-in-chief of The Journal of Infectious Diseases. Dr. Sears will succeed Martin S. Hirsch, MD, FIDSA, at the end of 2022, following his distinguished two decades of service to JID.

What You Need to Know About COVID-19 and the Omicron Variant

As scientists and clinicians learn more about the Omicron variant, IDSA highlights four things we know right now that can help reduce transmission and the risk of disease. 

IDSA and SHEA Statement on CDC Updated Guidance for Health Care Personnel Isolation and Quarantine to Mitigate Staffing Shortages

IDSA and the SHEA support the updated interim guidance from the CDC and Prevention for Managing Healthcare Personnel with SARS-CoV-2 Infection or Exposure to SARS-CoV-2 and Mitigating Healthcare Personnel Staffing Shortages.

IDSA Response to FDA’s Authorization of First Oral Antiviral for Treatment of COVID-19

IDSA supports the FDA’s emergency use authorization for Paxlovid, an oral anti-viral for the treatment of mild-to-moderate COVID-19. This authorization comes at a key moment as the nation and the world face climbing case counts and increased stress on health care systems.

HIVMA Chair Marwan Haddad, MD, MPH, Response to the National HIV/AIDS Strategy 2022 to 2025

On this World AIDS Day, HIVMA welcomes the release of the Biden-Harris Administration’s 2022 National HIV/AIDS Strategy, which will provide an important road map for ending HIV as an epidemic in the United States.

Statement On Omicron Variant

Discovery of the omicron variant in more than 14 countries to date is the latest evidence that the global COVID-19 pandemic is far from over.

Fourteen Institutions Receive the IDSA Antimicrobial Stewardship Center of Excellence Designation

The 14 awarded institutions have created stewardship programs led by infectious diseases-trained physicians and pharmacists that advance science in antimicrobial resistance.

New Guidance for Treating Antimicrobial-Resistant Infections Released

New guidance from the IDSA for treating three of the most common drug-resistant pathogens was published today on the IDSA website.

IDSA Response to FDA and CDC Decision to Expand COVID-19 Vaccine Booster Eligibility

IDSA supports the FDA and CDC decision to expand eligibility for COVID-19 vaccine boosters to include everyone age 18 and older.

IDSA and HIVMA Support BIO Preparedness Workforce Act

IDSA and HIVMA applaud the bipartisan introduction of the Bolstering Infectious Outbreaks (BIO) Preparedness Workforce Act by Sens. Tammy Baldwin (D-WI) and Susan Collins (R-ME).

IDSA Honors 199 Distinguished Clinicians, Scientists with FIDSA Designation

IDSA, the nation’s leading infectious diseases professional society, recognizes the distinguished clinicians and scientists from the United States and around the world who were elected this year to be Fellows of IDSA.